Drug Trial Radar · NCT05170048
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Evergreen Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD). Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are: 1. AREDS2 supplements (Control Group, N=30) 2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)
Conditions
- Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)
Interventions
EG-301Drug
The investigation drug, EG-301 Tablets 150mg, is for oral use.
AREDS2 supplementsDietary supplement
AREDS2 supplement is the stand of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events Assessment using CTCAE v5.0Time frame: Evaluation in 26 weeks treatment period, and 4 weeks safety follow up period.
- GA lesion size changeTime frame: From baseline to Week 26 treatment period
- Overall retinal sensitivityTime frame: From baseline to Week 26 treatment period
- BCVA in number of lettersTime frame: From baseline to Week 26 treatment period, and 4 weeks safety follow up period.
- Low luminance visual acuity (LLVA)Time frame: From baseline to Week 26 treatment period
- Binocular reading speedTime frame: From baseline to Week 26 treatment period
- Binocular critical print sizeTime frame: From baseline to Week 26 treatment period
- NEI-VFQ scoreTime frame: From baseline to Week 26 treatment period
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.